PHILADELPHIA, PA – URL Pharma, a leading specialty pharmaceutical company, announced that on December 10, 2008, the U.S. Food and Drug Administration (FDA) completed a current Good Manufacturing Practices (cGMP) inspection of its subsidiary Mutual Pharmaceutical Company, Inc. without any FDA Form 483 Observations.
An FDA Form 483, entitled Inspectional Observations, is used by FDA investigators to record observations of non-compliance with cGMPs after the FDA inspects a facility. This is the third consecutive time that the Company’s manufacturing facility has been inspected and that the FDA has not found any compliance issues.
“We pride ourselves on our commitment and dedication to quality,” said Richard H. Roberts, M.D., Ph.D., URL Pharma’s President and Chief Executive Officer, “and our latest successful FDA inspection further demonstrates URL Pharma’s commitment to providing the highest quality products to its customers.”
About URL Pharma
URL Pharma, Inc., headquartered in Philadelphia, Pennsylvania, is a leading specialty pharmaceutical company with fully integrated technology development, product development, manufacturing, and commercialization capabilities. After a long history of generic pharmaceutical research, development, and manufacturing, the Company has successfully transitioned to a profitable, technology-driven, specialty pharmaceutical business. The Company seeks to develop and commercialize scientifically and medically innovative products that address unmet medical needs for improvements in safety and efficacy. The Company’s profits are derived predominantly from its exclusive products and technologies. For more information, visit www.urlpharma.com.
For further information, please call 215-697-1900 or email@example.com.